Sort
82,697 grants matching “vaccine development”
MR191_ An Immunoprotectant for Marburg Virus
$1,000,000Ronald T Aimes · Mapp Biopharmaceutical, Inc. · SB1 · FY2018 · AI
Intranasal Vaccine Against Lyme Disease
$1,000,000Maria Gomes-Solecki · Immuno Technologies, Inc. · R44 · FY2023 · AI
A Vaccine for Lymphatic Filariasis, LFGuardâ¢
$1,000,000Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2021 · AI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
$1,000,000Michael David Alpert · Emmune, Inc · R44 · FY2023 · AI
Non-Human Primate Lymphoid Organ Chips for Vaccine Assessment
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2024 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
$1,000,000Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2021 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2017 · AI
STTR Phase II: VaxMAP a single dose multivalent vaccine to produce durable and cross-reactive immunity against various coronaviruses
$1,000,000Stephanie Deshayes · Tempo Therapeutics · · FY2023 · TIP
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
$1,000,000Arnab Basu · Microbiotix, Inc · R44 · FY2012 · AI
DNA prime / rVSV boost Multi-Antigen Universal Influenza Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2019 · AI
PIPP Phase I: Heterogeneous Model Integration for Infectious Disease Intelligence
$1,000,000John M Drake · University Of Georgia Research Foundation Inc · · FY2022 · BIO
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2014 · AI
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · SB1 · FY2025 · AI
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$1,000,000Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2019 · AI
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2021 · AI
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2013 · AI
Experimental Gonococcal Vaccine
$1,000,000Dominick Auci · Therapyx, Inc. · R44 · FY2022 · AI
Novel anti-viral agents to treat influenza
$1,000,000Dipanwita Basu · Alexander Biodiscoveries, Llc · R44 · FY2014 · AI
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)
$1,000,000Xiaowu Pang · Tengen Biomedical Co. · R42 · FY2023 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
Enhanced Surveillance for Newly preventable Diseases (ARI and AGE Surveillance) Rochester, NY
$1,000,000Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2017 · IP
Novel anti-viral agents to treat influenza
$1,000,000Dipanwita Basu · Alexander Biodiscoveries, Llc · R44 · FY2013 · AI
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
$1,000,000Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2022 · CA
Development of VLP vaccine for RSV
$1,000,000Jorge C Blanco · Sigmovir Biosystems, Inc. · R44 · FY2021 · AI
NINDS/UC Davis NeuroMab Hybridoma Facility
$1,000,000James S Trimmer · University Of California At Davis · U24 · FY2007 · NS